WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 562227
Description: XX-650-23 is an inhibitor of CREB (cAMP Response Element Binding protein).
MedKoo Cat#: 562227
Chemical Formula: C18H12N2O2
Exact Mass: 288.0899
Molecular Weight: 288.3
Elemental Analysis: C, 74.99; H, 4.20; N, 9.72; O, 11.10
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: XX-650-23; XX 650 23; XX65023;
IUPAC/Chemical Name: N-(4-Cyanophenyl)-3-hydroxy-2-naphthamide
InChi Key: DRBIYQSSEMTUJQ-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H12N2O2/c19-11-12-5-7-15(8-6-12)20-18(22)16-9-13-3-1-2-4-14(13)10-17(16)21/h1-10,21H,(H,20,22)
SMILES Code: O=C(NC1=CC=C(C#N)C=C1)C2=C(O)C=C3C=CC=CC3=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 288.3 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Chae HD, Cox N, Dahl GV, Lacayo NJ, Davis KL, Capolicchio S, Smith M, Sakamoto KM. Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways. Oncotarget. 2017 Dec 31;9(4):4301-4317. doi: 10.18632/oncotarget.23794. eCollection 2018 Jan 12. PubMed PMID: 29435104; PubMed Central PMCID: PMC5796975.
2: François S, Sen N, Mitton B, Xiao X, Sakamoto KM, Arvin A. Varicella-Zoster Virus Activates CREB, and Inhibition of the pCREB-p300/CBP Interaction Inhibits Viral Replication In Vitro and Skin Pathogenesis In Vivo. J Virol. 2016 Sep 12;90(19):8686-97. doi: 10.1128/JVI.00920-16. Print 2016 Oct 1. PubMed PMID: 27440893; PubMed Central PMCID: PMC5021407.
3: Mitton B, Chae HD, Hsu K, Dutta R, Aldana-Masangkay G, Ferrari R, Davis K, Tiu BC, Kaul A, Lacayo N, Dahl G, Xie F, Li BX, Breese MR, Landaw EM, Nolan G, Pellegrini M, Romanov S, Xiao X, Sakamoto KM. Small molecule inhibition of cAMP response element binding protein in human acute myeloid leukemia cells. Leukemia. 2016 Dec;30(12):2302-2311. doi: 10.1038/leu.2016.139. Epub 2016 May 23. PubMed PMID: 27211267; PubMed Central PMCID: PMC5143163.